Female Doctor Explaining Nanoparticles
First Asian Patient
Female Doctor
Image is not available
previous arrow
next arrow

NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
    NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
    Voting Rights and Shares Capital of the Company



    November 8–12, 2022

    SITC 2022

    More info
    October 23–26, 2022

    2022 ASTRO Annual Meeting

    More info


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer

    Download our latest
    Corporate Presentation